Ulka Vaishampayan, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    consulting
    Date added:
    11/08/2022
    Date updated:
    07/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Topic:
    consulting
    Date added:
    11/08/2022
    Date updated:
    07/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Exelixis
    Topic:
    consulting
    Date added:
    11/08/2022
    Date updated:
    07/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Topic:
    consulting
    Date added:
    11/08/2022
    Date updated:
    07/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Bayer
    Topic:
    prostate ca
    Date added:
    11/08/2022
    Date updated:
    07/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    sanofi
    Topic:
    prostate ca
    Date added:
    11/08/2022
    Date updated:
    07/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Gilead
    Topic:
    bladder ca
    Date added:
    07/13/2023
    Date updated:
    07/13/2023
Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes